Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 390

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

Open access
Pless, Miklos, Stupp, Roger, Ris, Hans-Beat, Stahel, Rolf A, Weder, Walter, Thierstein, Sandra, Gerard, Marie-Aline, Xyrafas, Alexandros, Früh, Martin, Cathomas, Richard, Zippelius, Alfred, Roth, Arnaud, Bijelovic, Milorad, Ochsenbein, Adrian, Meier, Urs R, Mamot, Christoph, Rauch, Daniel, Gautschi, Oliver, Betticher, Daniel C, Mirimanoff, René-Olivier, Peters, Solange · 2015 · The Lancet

Abstract

BACKGROUND One of the standard options in the treatment of stage IIIA/N2 non-small-cell lung cancer is neoadjuvant chemotherapy and surgery. We did a randomised trial to investigate whether the addition of neoadjuvant radiotherapy improves outcomes. METHODS We enrolled patients in 23 centres in Switzerland, Germany and Serbia. Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer and were randomly assigned to treatment groups in a 1:1 ratio. Those in the chemoradiotherapy group received three cycles of neoadjuvant chemotherapy (100 mg/m(2) cisplatin and 85 mg/m(2) docetaxel) followed by radiotherapy with 44 Gy in 22 fractions over 3 weeks, and those in the control group received neoadjuvant chemotherapy alone. All patients were scheduled to undergo surgery. Randomisation was stratified by centre, mediastinal bulk (less than 5 cm vs 5 cm or more), and weight loss (5% or more vs less than 5% in the previous 6 months). The primary endpoint was event-free survival. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00030771. FINDINGS From 2001 to 2012, 232 patients were enrolled, of whom 117 were allocated to the chemoradiotherapy group and 115 to the chemotherapy group. Median event-free survival was similar in the two groups at 12·8 months (95% CI 9·7-22·9) in the chemoradiotherapy group and 11·6 months (8·4-15·2) in the chemotherapy group (p=0·67). Median overall survival was 37·1 months (95% CI 22·6-50·0) with radiotherapy, compared with 26·2 months (19·9-52·1) in the control group. Chemotherapy-related toxic effects were reported in most patients, but 91% of patients completed three cycles of chemotherapy. Radiotherapy-induced grade 3 dysphagia was seen in seven (7%) patients. Three patients died in the control group within 30 days after surgery. INTERPRETATION Radiotherapy did not add any benefit to induction chemotherapy followed by surgery. We suggest that one definitive local treatment modality combined with neoadjuvant chemotherapy is adequate to treat resectable stage IIIA/N2 non-small-cell lung cancer. FUNDING Swiss State Secretariat for Education, Research and Innovation (SERI), Swiss Cancer League, and Sanofi.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)60294-x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 390

Metadata

Authors
Pless, M., Stupp, R., Ris, H.-B., Stahel, R. A., Weder, W., Thierstein, S., Gerard, M.-A., Xyrafas, A., Früh, M., Cathomas, R., Zippelius, A., Roth, A., Bijelovic, M., Ochsenbein, A., Meier, U. R., Mamot, C., Rauch, D., Gautschi, O., Betticher, D. C., Mirimanoff, R.-O., & Peters, S.
Venue
The Lancet
Publisher
Elsevier BV
Published
2015-09
Volume
386
Issue
9998
Pages
1049-1056
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2128147114
Cited by
390
References
15
FWCI
24.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(15)60294-x
The paper
Pless, M., Stupp, R., Ris, H.-B., Stahel, R. A., Weder, W., Thierstein, S., Gerard, M.-A., Xyrafas, A., Früh, M., Cathomas, R., Zippelius, A., Roth, A., Bijelovic, M., Ochsenbein, A., Meier, U. R., Mamot, C., Rauch, D., Gautschi, O., Betticher, D. C., . . . Peters, S. (2015). Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(15)60294-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.